Improving delivery of immune therapy for triple-negative breast cancer

Who could benefit from this research

What this research studies

This research focuses on enhancing the effectiveness of immune checkpoint inhibitors for patients with triple-negative breast cancer (TNBC), a type of cancer that often does not respond well to standard treatments. The approach involves using a novel system that utilizes platelets to deliver these inhibitors directly to the tumor site, improving their ability to activate the immune response against cancer cells. The study aims to increase the accumulation of this treatment at the tumor site and to modify the surrounding environment to make it more conducive to immune activity. By targeting both the tumor and the immune system, the research seeks to improve treatment outcomes for patients with TNBC.

Why it matters

Where this research is happening

• University of Wisconsin-Madison
  Madison, United States Active

Researchers

• Principal investigator: Hu, Quanyin — University of Wisconsin-Madison
• Study coordinator: Hu, Quanyin

Related research

Other NIH-funded projects on the same topics.

• Platelet-aided immunotherapy for triple-negative breast cancer

  Researchers are using platelets to carry PD-L1 blocking drugs directly to triple-negative breast tumors to help the immune system attack them.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11252603

• Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

  This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621786

• Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

  A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.

  NIH research Baltimore VA Medical Center · Baltimore, United States · NIH-11608792

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

• Rac-enhanced CAR-Macrophages against TNBC

  A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

  NIH research University of Louisville · Louisville, United States · NIH-11520503

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.